Two Form Vanguard For First US Rivals to Banzel Suspension
Executive Summary
Two companies now hold final US approvals for generics of Eisai’s Banzel oral suspension. But patent-litigation settlements could delay the entry of Bionpharma and Hikma to market.
You may also be interested in...
Hikma Offers Update On Plans For Advair Rival
Hikma has provided a trading update that sheds fresh light on plans for its delayed Advair generic, as well as revealing some new launches.
Hikma’s balance sheet is a bonus for chief Olafsson
As the US pricing situation continues to bite, industry veteran and newly-appointed Hikma chief executive officer Siggi Olafsson is confident the company’s superior balance sheet and diversified business operation, spread across three regions, will provide a competitive advantage. Dean Rudge reports.
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.